CNBC's "Fast Money" Intel, Visa and More Earnings on Tap, and Just How Bad Were Humana’s Earnings? 1/25/24
Jan 25, 2024
Discussions on Intel and Humana's latest earnings reports, including Intel's sliding shares despite positive results and Humana's significant drop in shares after lower-than-expected earnings. The chapter also covers topics such as Intel's position in the AI market, the drop in Humana's stock price due to higher medical costs, and the impact of Visa's earnings report on its stock.
AI Snips
Chapters
Transcript
Episode notes
Intel's Guidance Miss
- Intel's Q1 guidance missed estimates by $2 billion, impacting Mobileye, programmable solutions, and foundry businesses.
- Despite anticipated seasonality, investors reacted negatively to the magnitude of the miss.
Intel's Stock Potential
- Intel's stock has doubled since February 2023, reaching $50.
- Consider where to buy Intel during the sell-off rather than immediately selling.
Intel's Buy Ratings
- Intel has low buy ratings and low investor expectations currently.
- Given the revenue guide and share loss issues, a buying opportunity may arise around $30.